JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Bcr-Abl

Bcl-Abl is a constitutively activated chimeric tyrosine kinase which is the genetic abnormality expressed in patient with CML (chronic myeloid leukemia).

A8232 Nilotinib(AMN-107)
1 Citation

Target: Bcr-Abl

Summary: Bcr-Abl kinase inhibitor,selective

≥26.5 mg/mL
A2149 Bosutinib (SKI-606)
1 Citation

Target: Bcr-Abl|Src

Summary: Potent Abl/Src kinases

≥26.5 mg/mL
A2133 Saracatinib (AZD0530)
3 Citation

Target: Src

Summary: Src/Abl inhibitor,potent and selective

≥27.1 mg/mL
B1402 GZD824

Target: Bcr-Abl

Summary: Bcr-Abl inhibitor,novel orally bioavailable

≥36.25 mg/mL
B1404 DCC-2036 (Rebastinib)

Target: FLT3|Bcr-Abl|Tie-2|KDR

Summary: Bcr-Abl inhibitor

≥27.7 mg/mL